1,721,061 research outputs found
sj-pdf-1-jpc-10.1177_21501319221112272 – Supplemental material for Buprenorphine Waiver Attitudes Among Primary Care Providers
No full textSupplemental material, sj-pdf-1-jpc-10.1177_21501319221112272 for Buprenorphine Waiver Attitudes Among Primary Care Providers by Benjamin Lai, Ivana Croghan and Jon O. Ebbert in Journal of Primary Care & Community Health</p
Supplemental Material, Survey_Tool_Appendix - Social Relationship Quality Among Patients With Chronic Pain: A Population-Based Sample
No full textSupplemental Material, Survey_Tool_Appendix for Social Relationship Quality Among Patients With Chronic Pain: A Population-Based Sample by Lindsey M Philpot, Matthew E Schumann and Jon O Ebbert in Journal of Patient Experience</p
Supplemental Material - Cannabis in Cancer Survivors Who Report High Impact Chronic Pain: Findings from a 1500+ Patient Survey
No full textSupplemental Material for Cannabis in Cancer Survivors Who Report High Impact Chronic Pain: Findings from a 1500+ Patient Survey by Lindsey M. Philpot, Priya Ramar, Aminah Jatoi, Jordan Rosedahl, Rachel Canning, and Jon O. Ebbert in American Journal of Hospice and Palliative Medicine®</p
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity
No full textJon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, Michael&nbsp;V Burke, JT HaysMayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USAAbstract: Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an &alpha;4&beta;2 nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.Keywords: smoking cessation, chronic obstructive pulmonary disease, vareniclin
sj-docx-3-jtt-10.1177_1357633X241233788 - Supplemental material for Digitally enabled asynchronous remote medical management of anxiety and depression: A cohort study
No full textSupplemental material, sj-docx-3-jtt-10.1177_1357633X241233788 for Digitally enabled asynchronous remote medical management of anxiety and depression: A cohort study by Amichai Perlman, Yishai Pickman, Michael Dreyfuss, Itay Manes, Peter Bak, Daniel Souroujon, Edo Paz, Jon O Ebbert, and Dan Zeltzer in Journal of Telemedicine and Telecare</p
sj-docx-2-jtt-10.1177_1357633X241233788 - Supplemental material for Digitally enabled asynchronous remote medical management of anxiety and depression: A cohort study
No full textSupplemental material, sj-docx-2-jtt-10.1177_1357633X241233788 for Digitally enabled asynchronous remote medical management of anxiety and depression: A cohort study by Amichai Perlman, Yishai Pickman, Michael Dreyfuss, Itay Manes, Peter Bak, Daniel Souroujon, Edo Paz, Jon O Ebbert, and Dan Zeltzer in Journal of Telemedicine and Telecare</p
sj-docx-1-jtt-10.1177_1357633X241233788 - Supplemental material for Digitally enabled asynchronous remote medical management of anxiety and depression: A cohort study
No full textSupplemental material, sj-docx-1-jtt-10.1177_1357633X241233788 for Digitally enabled asynchronous remote medical management of anxiety and depression: A cohort study by Amichai Perlman, Yishai Pickman, Michael Dreyfuss, Itay Manes, Peter Bak, Daniel Souroujon, Edo Paz, Jon O Ebbert, and Dan Zeltzer in Journal of Telemedicine and Telecare</p
sj-docx-1-dhj-10.1177_20552076231216404 - Supplemental material for Implementation of eLearning solutions for patients with chronic pain conditions
No full textSupplemental material, sj-docx-1-dhj-10.1177_20552076231216404 for Implementation of eLearning solutions for patients with chronic pain conditions by Lindsey M. Philpot, Desiree J. Ahrens, Ryan J. Eastman, Arya B. Mohabbat, Elton A. Mosman, Priya Ramar, Karen J. Reinschmidt, Daniel L. Roellinger and Jon O. Ebbert in DIGITAL HEALTH</p
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
No full textJon O Ebbert, Kirk D Wyatt, J Taylor Hays, Eric W Klee, Richard D HurtMayo Clinic College of Medicine, Rochester, MN, USAAbstract: Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is efficacious and cost-effective. Smoking relapse and adverse treatment-related side effects may decrease medication adherence and patient satisfaction with varenicline. In the clinical setting, varenicline treatment can be optimized by reducing doses in patients who experience intolerable side effects, increasing the dose in partial responders, and providing long-term maintenance therapy for relapse prevention.Keywords: varenicline, tobacco dependence, smoking cessation, nicotine addictio
jpc-19-0087 – Supplemental material for Identifying Opportunities for Advancing Weight Management in Primary Care
No full textSupplemental material, jpc-19-0087 for Identifying Opportunities for Advancing Weight Management in Primary Care by Ivana T. Croghan, Jon O. Ebbert, Jane W. Njeru, Tamim I. Rajjo, Brian A. Lynch, Ramona S. DeJesus, Michael D. Jensen, Karen M. Fischer, Sean Phelan, Tara K. Kaufman, Darrell R. Schroeder, Lila J. Finney Rutten, Sarah J. Crane and Sidna M. Tulledge-Scheitel in Journal of Primary Care & Community Health</p
- …
